Brief: Innovation Pharmaceuticals Plans For Mid-Stage Trial Of New Treatment For Ulcerative Colitis
05/03/2020 14:25
March 5 (Reuters) - Innovation Pharmaceuticals Inc
IPIX.PK :
* INNOVATION PHARMACEUTICALS PLANS FOR PHASE 2 TRIAL OF NEW
TREATMENT FOR ULCERATIVE COLITIS
Source text for Eikon: ID:nGNX2d31Tg
Further company coverage: IPIX.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Innovation Pharmaceuticals
See all newsBrief: Innovation Pharmaceuticals Announces New Milestone At Beamed On Track To File 510(K) Submission To FDA In Q2 2024
Brief: Innovation Pharmaceuticals Provides Update On US Patent Applications Covering Use Of Brilacidin In Inflammatory Bowel Diseases, Coronaviruses And Fungal Diseases
Brief: Innovation Pharma Reports Enrollment In Phase 2 Trial Of Brilacidin For COVID-19 Tops 70%
Brief: Innovation Pharma Surpasses 50% Enrollment In Phase 2 Clinical Trial Of Brilacidin For COVID-19
Brief: Innovation Pharma Completes Interim Safety Data Review